Peptide Anticoagulant Drugs Market Size was valued at USD 0.25 Billion in 2023. The Global Peptide Anticoagulant Drugs industry is projected to grow from USD 0.43 Billion in 2024 to USD 1.58 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.52% during the forecast period (2024 - 2032). Anticoagulants are referred to as blood thinners. It is a chemical substance that prevents or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals, it helps to keep the bitten area unclotted long enough for the animal to obtain some blood.
Anticoagulants are related to and thrombolytic drugs and antiplatelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of peptide and anticoagulant drugs market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market.
According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014. Global prevalence of diabetes in adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period. However, the higher price of NOACs and lack of antidots for NOACs impede the market growth.
To make sure that they got ahead of Canadian market, Tiefeenbacher Pharmaceuticals launched a generic version of Apixaban in October, 2022. This is an oral anticoagulant for adults to prevent venous thromboembolism (VTE). In addition, it was FDA-approved after phase 3 clinical trials carried out in 2010 compared apixaban and enoxaparin. Consequently, it stops factor Xa and, therefore, decreases the risk of strokes and systemic emboli in patients with non-valvular atrial fibrillation.
In February 2022, Bayer AG won fast-track status from the US FDA drug regulators for new blood thinners that would block certain types of strokes. The FDA granted fast-track designation for the review of drug candidate Asundexian tested to prevent a repeat in patients who suffered a non-cardioembolic stroke from clogged vessels. During animal studies, Asundexian proved to be effective at reducing blood clotting without increasing bleeding time.
In June 2021, Johnson & Johnson's Janssen Pharmaceutical Cts, by inhibiting factor Xa.ompanies, announced that the US FDA had authorized two pediatric indications for XARELTO (rivaroxaban), an oral anticoagulant medication. Parenteral anticoagulants may be needed initially after five days before dosing XARELTO to ensure adequate anticoagulation during the transition from heparin to rivaroxaban therapy only if prothrombin time approaches the normal range. Women taking XARENTO should avoid pregnancy due to its fetal toxicity risks.
Rivaroxaban (RPIGAT) is an anticoagulant medication introduced by Natco Pharma in December 2020. It helps to thin the blood and prevent blood clots from forming; Bayer sells it as Xarelto.
As per the 2021 annual report of Pfizer Inc., in FY 2021, it invested $13,829 million which was an increase over $9,343 million spent in FY 2020. As stated in a press release by Biocon Biologics Limited on April 2022, R&D expenditures are expected to rise sharply at about 10-15% p.a. beginning FY23 due to a growing pipeline for new drugs contributing to accelerate future growth strategies.
The peptide and anticoagulant drugs Market is segmented on the basis of type, application and end users. The market by type is hormonal, antibiotic, ACE inhibitor antifungal, other peptide drugs, and Oral Anticoagulants. Hormonal is sub-segmented into categorized into insulin teriparatide and leuprolide acetate. Antibiotic is categorized into eptifibatide and warfarin. On the basis of anticoagulants, the market is sub-segmented into enoxaparin sodium and heparin sodium. and on the basis of application, the market is sub-segmented into diabetes, cancer, infectious diseases, cancer, osteoporosis, cardiology, gynecology, other. On the basis of end users, the market is segmented into hospitals, research centers, and diagnostic centers.
On the basis of region, the peptide and anticoagulant drugs Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. According to the cancer organization in 2017, it was found that 63,410 new cases of breast carcinoma in situ, 252,710 new cases of invasive breast cancer, and 40,610 breast cancer deaths.
The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players for peptide and anticoagulant drugs market
It is estimated that North America dominated the peptide and anticoagulant drugs Market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. According, to WHO in it was estimated that diabetes was the cause of 1.6 million deaths. Most of all deaths related to high blood glucose occur before the age of 70 years. WHO also projected that diabetes will be the seventh leading cause of death in 2030 which can be the major leading factor in the growth of market in this region.
Europe stood second largest in the peptide and anticoagulant drugs market owing to the increasing use of tobacco. According to the Cancer Research UK, 359,960 cases of cancer were found in 2015. Also, 35,620 deaths caused due to lung cancer in this region due to change in lifestyle which can enhance the growth of market.
Asia-Pacific was projected to be the fastest growing region for the peptide and anticoagulant drugs Market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The international diabetes federation estimated 72,946,400 cases of diabetes in India in 2017. Such a high incidence of diabetes cases favors the market growth in this region.
The Middle East and Africa holds the least share in the peptide and anticoagulant drugs Market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2030 | Â USD 1.58 Billion: 2032 |
| Compound Annual Growth Rate (CAGR) | 4.52%: 2032 |
| Base Year | 2021 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, technology, application, and end-users. |
| Geographies Covered | Americas, Europe, Asia Pacific and the Middle East and Africa |
| Countries Covered | China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific |
| Key Companies Profiled | Masimo. (the U.S.)BD. (U.S.)Smiths Group Plc. (the U.S.)F. Hoffmann-La Roche Ltd (Europe)Bayer AG (Europe)Rotech Healthcare Inc. (U.S.)Chart Industries (U.S.)ACare Technology (Asia Pacific) |
| Key Market Opportunities | Key market opportunities for the peptide and anticoagulant drugs market include the rising prevalence of chronic diseases, advancements in biotechnology, and increasing demand for targeted therapies. |
| Key Market Dynamics | Key market dynamics for the peptide and anticoagulant drugs market include rising prevalence of chronic diseases, increasing geriatric population, and advancements in drug delivery technologies. |
Frequently Asked Questions (FAQ) :
The high price of NOACs and lack of antidotes can prevent peptide & anticoagulants drug market growth.
The study includes segments like antibiotics, hormonal, other peptide drugs, ACE inhibitor antifungal, and anticoagulants.
The segments are enoxaparin sodium and heparin sodium for discussion.
North America would be well-placed to achieve the highest valuation for peptide & anticoagulants drugs market.
The fastest-growing region for peptide & anticoagulants drugs market would be the Asia Pacific.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
